Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revolution Medicines, Inc.

40.61
-0.0600-0.15%
Volume:1.30M
Turnover:52.52M
Market Cap:7.55B
PE:-11.35
High:41.17
Open:40.22
Low:39.20
Close:40.67
Loading ...

Stifel Nicolaus Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
11 Nov 2024

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight

GuruFocus.com
·
09 Nov 2024

Bank of America Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
08 Nov 2024

Revolution Medicines Inc reports results for the quarter ended in January 1 - Earnings Summary

Reuters
·
07 Nov 2024

Revolution Medicines Inc : Needham Raises Target Price to $68 From $61

THOMSON REUTERS
·
07 Nov 2024

Revolution Medicines price target raised to $70 from $57 at Piper Sandler

TIPRANKS
·
07 Nov 2024

Revolution Medicines price target raised to $64 from $62 at H.C. Wainwright

TIPRANKS
·
07 Nov 2024

Revolution Medicines, Inc. : H.c. Wainwright Raises Target Price to $64 From $62

THOMSON REUTERS
·
07 Nov 2024

Revolution Medicines Q3 Loss Narrows; Reaffirms Full-Year Guidance

MT Newswires Live
·
07 Nov 2024

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
07 Nov 2024

Revolution Medicines Inc : Piper Sandler Raises Target Price to $70 From $57

THOMSON REUTERS
·
07 Nov 2024

Revolution Medicines: Strong Buy Rating Backed by Financial Stability and Promising Cancer Treatment Advances

TIPRANKS
·
07 Nov 2024

Revolution Medicines reports Q3 EPS (94c), consensus (89c)

TIPRANKS
·
07 Nov 2024

Revolution Medicines Q3 EPS $(0.94) Misses $0.87 Estimate

Benzinga
·
07 Nov 2024

BRIEF-Revolution Medicines Q3 EPS USD -0.94

Reuters
·
07 Nov 2024

Revolution Medicines Q3 Operating Expenses USD 175.712 Million

THOMSON REUTERS
·
07 Nov 2024

Revolution Medicines: Projects Current Cash, Cash Equivalents and Marketable Securities Can Fund Planned Operations Into 2027

THOMSON REUTERS
·
07 Nov 2024

Revolution Medicines to Participate in Upcoming Investor Conferences

GlobeNewswire
·
05 Nov 2024

Promising Clinical Trial Results and Strategic Combination Bolster Buy Rating for Revolution Medicines

TIPRANKS
·
04 Nov 2024

Revolution Medicines price target raised to $62 from $56 at H.C. Wainwright

TIPRANKS
·
04 Nov 2024